Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
347
resultados
Última actualización
27/07/2026 [09:40:00]
Resultados 325 a 347 de 347
Resumen de: CN122103332A
本发明涉及生物医药领域，提供了一种抗磷酸化CREB（Ser133）抗体及其应用。本发明所提供的抗体J20C选自下列至少之一：（a）具有SEQ ID NO:3、4和5所示的轻链CDR序列，以及具有SEQ ID NO:6、7和8所示的重链CDR序列；(b)轻链可变区具有SEQ ID NO:1所示的氨基酸序列，且重链可变区具有SEQ ID NO:2所示的氨基酸序列。此外，本发明还公开了利用此抗体改造的单链抗体，具有较高的灵敏度和特异性。可以作为阿尔茨海默病和癫痫的发生和进展的辅助诊断工具。
Resumen de: CN122108702A
0001 本发明提供了基于质谱成像技术的动物脑部代谢物鉴定方法及应用，基于质谱成像技术，建立小鼠脑组织切片的内源性代谢物DESI‑MSI分析方法，包括以下步骤：制备代谢物对照品成像样品和大脑组织切片成像样品后，其中多个动物脑组织贴于同一载玻片，采用对照品成像样品进行质谱成像条件优化，采用大脑组织切片成像样品质谱成像分析；结合组织形态学特征将生物样品的图像分割成多个结构区域；针对所述结构区域，进行多元统计分析，获得不同结构区域的差异代谢物；基于母离子和特征子离子轮廓进行代谢物鉴定；用于疾病机制研究和药物对疾病的干预效果评价。
Resumen de: CN122109524A
0001 本发明为基于磁珠和免疫qPCR的ELISA蛋白定量检测方法、试剂盒及其应用，涉及一种用于检测样本中目标分析物的试剂盒及其检测方法，所述试剂盒包括第一试剂和第二试剂，第一试剂包含修饰有针对分析物特异性第一结合剂的磁性颗粒；第二试剂包含针对分析物特异性的第二结合剂，且该第二结合剂与核酸条形码偶联；第一结合剂和第二结合剂结合到目标分析物的不同表位。本发明的试剂盒和检测方法，具有高灵敏度、多重蛋白质检测的优势，尤其适用于低丰度蛋白质生物标志物的检测。
Resumen de: WO2025059486A1
The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).
Resumen de: CN122109520A
0001 本申请公开了一种三维立体双极ECL侧向流免疫试纸条及其在免疫检测中的应用，所述的三维立体双极ECL侧向流免疫试纸条包括三维立体双极电极片、侧向流免疫试纸条和连接垫；所述的三维立体双极电极片在下，所述的侧向流免疫试纸条和连接垫在上；所述的三维立体双极电极片采用分层设计，包括电极片层一和电极片层二；所述的电极片层二在下，电极片层一在上；所述电极片层二包括阳性驱动电极；所述的阳性驱动电极包括阳性驱动电极首端、阳性驱动电极尾端及其连接导线。本发明首次设计一种三维立体双极电极片，该电极片包括电极片层一及电极片层二，通过具有粘贴性的背胶结合。这打破了传统双极ECL电极片的缺点，更适合现场快速检测的需求。
Resumen de: WO2026111092A1
The present invention relates to a novel microRNA for early in vitro diagnosis of Alzheimer's disease and a convergence diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained through molecular analysis has a different expression level in the plasma of normal, mild cognitive impairment, and Alzheimer's dementia patient groups, and has the effect of reducing the expression level of proteins associated with mild cognitive impairment and Alzheimer's dementia. Therefore, the present invention has the effect that mild cognitive impairment and Alzheimer's dementia as well as early diagnosis of Alzheimer's dementia can be screened and diagnosed by non-invasively using the novel miRNA present in plasma as a molecular diagnostic marker.
Resumen de: US20260144764A1
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
Resumen de: US20260147006A1
0000 The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low α value, or the M1PAM and an acetylcholinesterase inhibitor.
Resumen de: WO2026108046A1
Provided are a monoclonal antibody against a p-Tau217 protein and the use thereof. Specifically, provided is an antibody targeting a p-Tau217 protein or an antigen-binding fragment thereof. The provided antibody can specifically recognize and bind to a p-Tau217 protein without recognizing p-Tau181 and non-phosphorylated Tau proteins, and can be used in the preparation of a detection preparation or kit for diagnosing diseases associated with the p-Tau217 protein, such as Alzheimer's disease.
Resumen de: US20260146088A1
0000 The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Resumen de: US20260146040A1
0000 Use of caseinolytic protease P (ClpP) function and/or concentration as a biomarker for predicting the response of a neoplastic disease, preferably cancer or another disease where enhancing ClpP activity may provide a therapeutic benefit, to a compound of Formula I. In other aspects it relates to methods and kits, as well as methods of treatment involving the use of the biomarker.
Resumen de: AU2024388718A1
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
Resumen de: US20260147005A1
0000 The present disclosure relates to use of tear fluid neuropeptide Y (NPY) level for diagnosis, prognosis, assessment and therapy stratification of corneal nerve damage or loss, corneal neuropathy, corneal neuropathic pain, corneal neuralgia, ocular disease, or peripheral neuropathy.
Resumen de: WO2026112321A1
The invention relates to a method of detecting ORF2p and/or ORF Ip in a sample comprising: a) enriching ORF2p in the sample; and b) detecting ORFp2 and/or ORF Ip by mass spectrometry. The invention also relates to a method of diagnosing a subject with a disease or disorder (e.g., cancer) comprising detecting ORF2p and/or ORF Ip in a biological sample from the subject, comprising: a) enriching ORF2p in the sample; and b) detecting ORFp2 and/or ORF Ip by mass spectrometry.
Resumen de: WO2026112102A1
The invention relates to systems, methods, and computer-readable media for automated assessment of volumetric changes in brain regions of interest in preclinical animal models. Digital images of brain tissue cross-sections are processed using a convolutional neural network (CNN) to isolate regions of interest, followed by a transformer-based artificial intelligence model utilizing axial and patched attention for pixel classification. Segmentation accuracy is enhanced through a topological data analysis (TDA) algorithm, which refines results by constructing and evaluating simplicial complexes to ensure anatomical continuity. The refined segmentation data is used to calculate three-dimensional volumes based on the Cavalieri principle, and the results are displayed or stored for further analysis. The system offers improved accuracy, efficiency, and consistency over manual methods, supporting preclinical evaluation of therapies targeting neuropathology. Applications include tracking volumetric changes over time and facilitating high-throughput analyses in neurodegenerative disease research.
Resumen de: WO2026110866A1
The present invention addresses the problem of providing, as a means for detecting soluble receptor-type protein tyrosine phosphatase Z (soluble PTPRZ) that can be a biomarker for a glioma, an antibody capable of specifically binding to the soluble PTPRZ. Moreover, the present invention addresses the problem of providing: a novel method for quantifying the protein mass of the soluble PTPRZ; and a standard substance for use in the quantification of said method. Provided is a standard substance for use in quantifying a glycoprotein to which a human natural killer-1 sugar chain (HNK-1 sugar chain) is bound, the standard substance comprising a sugar chain complex including at least two HNK-1 sugar chains.
Resumen de: US20260146231A1
The disclosure provides a method for producing brain organoids, brain organoids produced by the method, and use of the brain organoids for characterizing the activity of a substance in brain tissue.
Resumen de: WO2026111415A1
The present invention relates to a phosphorylated tau-gold nanoparticle complex, a method for manufacturing the same, and a drug screening method using same. The phosphorylated tau-gold nanoparticle complex manufactured according to the method for manufacturing a phosphorylated tau-gold nanoparticle complex of the present invention enables evaluation of how effectively a specific drug degrades phosphorylated tau aggregates and thus can be advantageously used for high-throughput screening of drugs for preventing or treating primary tauopathies.
Resumen de: WO2024229569A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Resumen de: US20260146997A1
Idiopathic Parkinson's disease (iPD) is a multi-system disorder, and the debilitating motor stage of iPD can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD) and gastrointestinal symptoms. Widespread immune dysregulation has been reported in clinically diagnosed iPD, but the existence of immune deficits during the prodromal stage has yet to be thoroughly investigated. Here, it was shown that multiple stages of iPD, including the pre-motor prodromal stage, can be stratified according to the immuno-metabolic response to stimulation of peripheral blood immune cells ex vivo. Peripheral blood monocytes from RBD patients displayed increased stimulation-dependent secretion of inflammatory cytokines, including TNF, IL-1β, and IL-8, which peaks in the prodromal stage and successively diminishes as PD progresses. Furthermore, T lymphocyte mitochondrial health was correlated with stimulation-evoked cytokine secretion across patients with RBD, early-stage iPD, and moderate-stage iPD. The results disclosed here have broad implications for mechanistic understanding of how peripheral inflammation may drive disease progression, and it reveals novel biomarkers to enable patient stratification and progression monitoring for clinical trials based on immune endophenotypes.
Resumen de: WO2026112265A1
The presently described and claimed technology relates immunoassay methods of assessing a subject's Alzheimer's Disease status and zygosity for the APOE ε4 allele.
Nº publicación: AU2024357691A1 28/05/2026
Solicitante:
VERAVAS INC
PHANES BIOTECH INC
VERAVAS, INC.
PHANES BIOTECH, INC.
Resumen de: AU2024357691A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
BOPI
Sede Electrónica
